Northwestern University Institutional Biosafety Committee
Meeting Minutes

Date: 06/17/2026 11:00 AM
Called to Order: 11:01 AM
Adjourned: 12:44 PM
Location: 345 E Superior St, Suite 1522, Chicago, IL 60611
Northwestern University conducts some or all of its IBC meetings via teleconference. A public meeting notice was posted; no comments or attendance requests were received. Attendees of a Northwestern IBC meeting are reminded of confidentiality and conflict of interest expectations. A public meeting notice was posted on the Research Safety website and no public comment was received.

IBC Members

Name	Committee Role	Attendance
Mary Hummel	Chair	Present
Greg Smith	Chair	Present
Gregory Beitel	Member	Present
Jennifer Brace	Member	Present
Jacob Class	Member	Present
Alexis Demonbreun	Member	Present
Adriana Ferreira	Member	Present
Robert Foreman	Member	Present
Susan Fox	Member	Absent
Lucy Godley	Member	Absent
Erica Hartmann	Member	Present
Sydni Hill	Member	Present
Robert Holmgren	Member	Present
Changhwa Hwang	Member	Present
Sarah Kopp	Member	Absent
Maciej Lesniak	Member	Absent
Stephen Levin	Member	Present
Liming Li	Member	Absent
Michael McRaven	Member	Absent
Jeremy T Ritzert	Member	Present
Irina Shepotinovskaya	Member	Absent
Suchitra Swaminathan	Member	Present
Clyde Yancy	Member	Absent
Nicolette Zielinski-Mozny	Member	Present
Raza Akbar	Alternate	Absent
Robert Birkett	Alternate	Present
Mandy Kozlowski	Alternate	Present
Alicia McLuckie	Alternate	Absent
Marina Zelivyanskaya	Alternate	Present

Name	Committee Role	Attendance
James Zewe	Alternate	Present
Robert Foreman	Administrator	Present
Michael Hantak	Administrator	Present
Sarah Kopp	Administrator	Absent
Iwona Spath	Administrator	Present

Registrations for Full-Committee Review

Research Group	Principal Investigator	Submission Type
Amendment/CR for BIO20250053	Kelly Bachta	Amendment/CR
Amendment/CR for BIO20220140	Ankit Bharat	Amendment/CR
Chandel Lab	Navdeep Chandel	Initial Protocol
Amendment/CR for BIO20230124	Bria Coates	Amendment/CR
David (Abel) Lab	Abel David	Initial Protocol
Khan Lab	Seema Khan	Initial Protocol
Liu (Huiping) Lab	Huiping Liu	Initial Protocol
Martin Lab	Aline Martin	Initial Protocol
Amendment/CR for BIO20230066	Sanjiv Shah	Amendment/CR
Stupp SQI - Chemistry Chicago	Samuel Stupp	Initial Protocol
Amendment for BIO20250027	Christine Wang	Amendment
Wang (Chyung-Ru) Lab	Chyung-Ru Wang	Initial Protocol
Amendment for BIO20230038	Bin Zhang	Amendment

Approval of Previous Meeting Minutes

Previous Meeting Date: 5/20/26
Determination: Approved
Comments: A Committee Member made a motion to approve the meeting minutes. The Committee unanimously supported the motion.

Meeting Minutes

Review of Amendment/CR for BIO20250053

Amendment/CR

Principal Investigator: Kelly Bachta

Submission ID: BIO20250053-AMCR0001

Applicable NIH Guidelines:

- Section III-F-2
- Section III-D-4-b
- Section III-D-4
- Section III-F-7
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-2
- Section III-D
- Section III-F-8
- Section III-F-6

Highest Applicable Containment Level for Proposed Look: BSL-2

Determination: Approved

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Amendment/CR for BIO20220140

Amendment/CR

Principal Investigator: Ankit Bharat

Submission ID: BIO20220140-AMCR0002

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-7
- Section III-E-3-a
- Section III-D-4-c-(1)
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

Highest Applicable Containment Level for Proposed Look: BSL-2

Determination: Approved

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Chandel Lab

Initial Protocol

Principal Investigator: Navdeep Chandel

Submission ID: BIO20260016

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-D-3-a
- Section III-F-8

Highest Applicable Containment Level for Proposed Look: BSL-2+

Determination: Approved

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Amendment/CR for BIO20230124

Amendment/CR

Principal Investigator: Bria Coates

Submission ID: BIO20230124-AMCR0002

Applicable NIH Guidelines:

- Section III-D-7
- Section III-E-3-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-4-c-(2)
- Section III-E-2-b-(5)
- Section III-D-2
- Section III-D
- Section III-F-8

Highest Applicable Containment Level for Proposed Look: BSL-2

Determination: Approved

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of David (Abel) Lab

Initial Protocol

Principal Investigator: Abel David

Submission ID: BIO20260007

Applicable NIH Guidelines:

- Section III-F
- Section III-F-1
- Section III-F-8

Highest Applicable Containment Level for Proposed Look: BSL-2

Determination: Approved with minor modifications

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

Review of Khan Lab

Initial Protocol

Principal Investigator: Seema Khan

Submission ID: BIO20260020

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4-b
- Section III-D-4-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Highest Applicable Containment Level for Proposed Look: BSL-2

Determination: Approved

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Liu (Huiping) Lab

Initial Protocol

Principal Investigator: Huiping Liu

Submission ID: BIO20260011

Applicable NIH Guidelines:

- • Section III-D-4
- • Section III-F
- • Section III-F-8-C-II
- • Section III-F-1
- • Section III-F-8-C-VII
- • Section III-D
- • Section III-F-8

Highest Applicable Containment Level for Proposed Look: BSL-2

Determination: Approved

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Martin Lab

Initial Protocol

Principal Investigator: Aline Martin

Submission ID: BIO20260014

Applicable NIH Guidelines:

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-1
- SSection III-F-8

Highest Applicable Containment Level for Proposed Look: BSL-2

Determination: Approved with minor modifications

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

Review of Amendment/CR for BIO20230066

Amendment/CR

Principal Investigator: Sanjiv Shah

Submission ID: BIO20230066-AMCR0001

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D
- Section III-F-8

Highest Applicable Containment Level for Proposed Look: BSL-2

Determination: Approved

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Stupp SQI - Chemistry Chicago

Initial Protocol

Principal Investigator: Samuel Stupp

Submission ID: BIO20260023

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

Highest Applicable Containment Level for Proposed Look: BSL-2

Determination: Approved

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Amendment for BIO20250027

Amendment

Principal Investigator: Christine Wang

Submission ID: BIO20250027-AM0001

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-2
- Section III-D
- Section III-D-3

Highest Applicable Containment Level for Proposed Look: BSL-2

Determination: Approved

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Wang (Chyung-Ru) Lab

Initial Protocol

Principal Investigator: Chyung-Ru Wang

Submission ID: BIO20260019

Applicable NIH Guidelines:

- Section III-F-2
- Section III-E-3
- Section III-F-3
- Section III-D-4-b
- Section III-E-3-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-E-1
- Section III-F-8

Highest Applicable Containment Level for Proposed Look: BSL-3

Determination: Approved

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Amendment for BIO20230038

Amendment

Principal Investigator: Bin Zhang

Submission ID: BIO20230038-AM0002

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Highest Applicable Containment Level for Proposed Look: BSL-2

Determination: Approved with minor modifications

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

Administratively-Approved Exempt Registrations and Amendments

Continuing Review for BIO20250085
Continuing Review

Principal Investigator: Daniel Brat

Submission ID: BIO20250085-CR0001

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 6/12/2026

Amendment/CR for BIO20240100
Amendment/CR

Principal Investigator: Daniel Brat

Submission ID: BIO20240100-AMCR0001

Applicable NIH Guidelines:

Containment Level: BSL-2

Approval Date: 6/3/2026

Amendment for BIO20220069
Amendment

Principal Investigator: Serdar Bulun

Submission ID: BIO20220069-AM0004

Applicable NIH Guidelines:

- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 6/8/2026

Amendment/CR for BIO20220083

Amendment/CR

Principal Investigator: Qi Cao

Submission ID: BIO20220083-AMCR0001

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D
- Section III-D-3

Containment Level: BSL-2

Approval Date: 5/21/2026

Amendment for BIO20220112

Amendment

Principal Investigator: Isabelle De Plaen

Submission ID: BIO20220112-AM0002

Applicable NIH Guidelines:

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2

Approval Date: 5/22/2026

Amendment for BIO20260024

Amendment

Principal Investigator: Daniel Dombeck

Submission ID: BIO20260024-AM0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2

Approval Date: 5/22/2026

Continuing Review for BIO20240126

Continuing Review

Principal Investigator: Vinayak Dravid

Submission ID: BIO20240126-CR0002

Applicable NIH Guidelines:

- Section III-F
- Section III-F-8

Containment Level: BSL-1

Approval Date: 6/8/2026

Continuing Review for BIO20230060

Continuing Review

Principal Investigator: Igor Efimov

Submission ID: BIO20230060-CR0003

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D
- Section III-F-8

Containment Level: BSL-2

Approval Date: 5/21/2026

Amendment for BIO20220034

Amendment

Principal Investigator: Lillian Eichner

Submission ID: BIO20220034-AM0003

Applicable NIH Guidelines:

- • Section III-D-4
- • Section III-F
- • Section III-F-1
- • Section III-D-1
- • Section III-D-2
- • Section III-D
- • Section III-D-3
- • Section III-F-8

Containment Level: BSL-2

Approval Date: 5/21/2026

Continuing Review for BIO20220100

Continuing Review

Principal Investigator: Arthur Felse

Submission ID: BIO20220100-CR0002

Applicable NIH Guidelines:

- Section III-F-2
- Section III-F
- Section III-E
- Section III-F-1

Containment Level: BSL-2

Approval Date: 2/20/2026

Continuing Review for BIO20220125

Continuing Review

Principal Investigator: Ruli Gao

Submission ID: BIO20220125-CR0002

Applicable NIH Guidelines:

- Section III-F-2
- Section III-F

Containment Level: BSL-2

Approval Date: 6/2/2026

Amendment for BIO20240150

Amendment

Principal Investigator: Jaime Garcia-Anoveros

Submission ID: BIO20240150-AM0001

Applicable NIH Guidelines:

- Section III-F-2
- Section III-E-3
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2

Approval Date: 5/28/2026

Continuing Review for BIO20220108

Continuing Review

Principal Investigator: Changiz Geula

Submission ID: BIO20220108-CR0002

Applicable NIH Guidelines:

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2

Approval Date: 6/3/2026

Amendment for BIO20220017

Amendment

Principal Investigator: Nayereh Ghoreishi

Submission ID: BIO20220017-AM0020

Applicable NIH Guidelines:

- Section III-D-4-b
- Section III-D-4
- Section III-D-4-c-(1)
- Section III-F
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Approval Date: 5/29/2026

Amendment for BIO20220078

Amendment

Principal Investigator: Nathan Gianneschi

Submission ID: BIO20220078-AM0002

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4
- Section III-E
- Section III-F-1
- Section III-D

Containment Level: BSL-2

Approval Date: 5/20/2026

Continuing Review for BIO20250040

Continuing Review

Principal Investigator: Matthew Glucksberg

Submission ID: BIO20250040-CR0001

Applicable NIH Guidelines:

- Section III-F
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2+

Approval Date: 6/16/2026

Continuing Review for BIO20230063

Continuing Review

Principal Investigator: Lucy Godley

Submission ID: BIO20230063-CR0002

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 5/24/2026

Continuing Review for BIO20220072

Continuing Review

Principal Investigator: Yogesh Goyal

Submission ID: BIO20220072-CR0003

Applicable NIH Guidelines:

- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3

Containment Level: BSL-2

Approval Date: 6/8/2026

Continuing Review for BIO20250089

Continuing Review

Principal Investigator: Alan Hauser

Submission ID: BIO20250089-CR0001

Applicable NIH Guidelines:

- Section III-F-2
- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-4-c
- Section III-F-8-C-VIII
- Section III-F-8
- Section III-F-6

Containment Level: BSL-2

Approval Date: 5/29/2026

Amendment for BIO20250033

Amendment

Principal Investigator: Amy Heimberger

Submission ID: BIO20250033-AM0003

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-F-2
- Section III-E-3
- Section III-E-3-a
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3-a
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Approval Date: 6/15/2026

Hoffman Lab

Initial Protocol

Principal Investigator: Brian Hoffman

Submission ID: BIO20260030

Applicable NIH Guidelines:

Containment Level: N/A

Approval Date: 5/27/2026

Amendment/CR for BIO20240131

Amendment/CR

Principal Investigator: Brian Hoffman

Submission ID: BIO20240131-AMCR0001

Applicable NIH Guidelines:

Containment Level: N/A

Approval Date: 5/27/2026

Continuing Review for BIO20240101

Continuing Review

Principal Investigator: Michael Jewett

Submission ID: BIO20240101-CR0002

Applicable NIH Guidelines:

- Section III-F-2
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-F-4
- Section III-F-8

Containment Level: BSL-1

Approval Date: 6/5/2026

Amendment/CR for BIO20240051

Amendment/CR

Principal Investigator: Atsushi Kato

Submission ID: BIO20240051-AMCR0001

Applicable NIH Guidelines:

- Section III-F
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2+

Approval Date: 5/29/2026

Continuing Review for BIO20220098

Continuing Review

Principal Investigator: Daniel Kim

Submission ID: BIO20220098-CR0002

Applicable NIH Guidelines:

Containment Level: BSL-1

Approval Date: 5/22/2026

Continuing Review for BIO20250032

Continuing Review

Principal Investigator: Hojoon Lee

Submission ID: 20250032-CR0001

Applicable NIH Guidelines:

- Section III-F-2
- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-F-8

Containment Level: BSL-2

Approval Date: 5/31/2026

Continuing Review for BIO20220146

Continuing Review

Principal Investigator: Shu Qian Liu

Submission ID: BIO20220146-CR0002

Applicable NIH Guidelines:

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-8-C-VII
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Approval Date: 6/1/2026

Continuing Review for BIO20250097

Continuing Review

Principal Investigator: Elizabeth Managlia

Submission ID: BIO20250097-CR0001

Applicable NIH Guidelines:

- Section III-F
- Section F-8

Containment Level: BSL-1

Approval Date: 6/16/2026

Marko Lab

Initial Protocol

Principal Investigator: John Marko

Submission ID: BIO20260029

Applicable NIH Guidelines:

- Section III-F-2
- Section III-F
- Section III-F-8-C-II
- Section III-F-1
- Section III-F-8-C-VIII

Containment Level: BSL-2

Approval Date: 5/26/2026

Continuing Review for BIO20230133

Continuing Review

Principal Investigator: John Marko

Submission ID: BIO20230133-CR0002

Applicable NIH Guidelines:

- Section III-F-2
- Section III-F
- Section III-F-8-C-II
- Section III-F-1
- Section III-F-8-C-VIII

Containment Level: BSL-2

Approval Date: 5/21/2026

Continuing Review for BIO20240106

Continuing Review

Principal Investigator: Johanna Melo-Cardenas

Submission ID: BIO20240106-CR0002

Applicable NIH Guidelines:

- Section III-E-3
- Section III-E-3-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2+

Approval Date: 5/29/2026

Amendment for BIO20240043

Amendment

Principal Investigator: Luisa Morales-Nebreda

Submission ID: BIO20240043-AM0009

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-7
- Section III-D-4
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2+

Approval Date: 5/18/2026

Continuing Review for BIO20230007

Continuing Review

Principal Investigator: Adam Murphy

Submission ID: BIO20230007-CR0002

Applicable NIH Guidelines:

Containment Level: BSL-2

Approval Date: 5/20/2026

Amendment/CR for BIO20240196

Amendment/CR

Principal Investigator: Peter Penzes

Submission ID: BIO20240196-AMCR0001

Applicable NIH Guidelines:

- Section III-D-4-b
- Section III-D-4-a
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 5/27/2026

Amendment for BIO20220043

Amendment

Principal Investigator: Karen Ridge

Submission ID: BIO20220043-AM0001

Applicable NIH Guidelines:

- Section III-D-7
- Section III-E-3-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-F-8

Containment Level: BSL-2

Approval Date: 5/5/2026

Amendment for BIO20240070

Amendment

Principal Investigator: Adrian Rodriguez Contreras

Submission ID: BIO20240070-AM0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-E

Containment Level: BSL-1

Approval Date: 6/16/2026

Continuing Review for BIO20220009

Continuing Review

Principal Investigator: Paul Schumacker

Submission ID: BIO20220009-CR0002

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Approval Date: 5/27/2026

Continuing Review for BIO20220039

Continuing Review

Principal Investigator: Vipul Shukla

Submission ID: BIO20220039-CR0002

Applicable NIH Guidelines:

- Section III-D-4-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 6/2/2026

Amendment/CR for BIO20250074

Amendment/CR

Principal Investigator: Wilton Snead

Submission ID: BIO20250074-AMCR0001

Applicable NIH Guidelines:

- Section III-F-2
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2+

Approval Date: 5/27/2026

Amendment for BIO20230024

Amendment

Principal Investigator: Dalton Surmeier Jr

Submission ID: BIO20230024-AM0003

Applicable NIH Guidelines:

- Section III-E-3
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-F-8

Containment Level: BSL-2

Approval Date: 5/29/2026

Continuing Review for BIO20230024

Continuing Review

Principal Investigator: Dalton Surmeier Jr

Submission ID: BIO20230024-CR0003

Applicable NIH Guidelines:

- Section III-E-3
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-F-8

Containment Level: BSL-2

Approval Date: 5/28/2026

Continuing Review for BIO20240176

Continuing Review

Principal Investigator: Praveen Thumbikat

Submission ID: BIO20240176-CR0001

Applicable NIH Guidelines:

- Section III-F-2
- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2

Approval Date: 5/29/2026

Amendment for BIO20230074

Amendment

Principal Investigator: Matthew Tresch

Submission ID: BIO20230074-AM0001

Applicable NIH Guidelines:

Containment Level: BSL-1

Approval Date: 5/29/2026

Weiss (Eric) Lab

Initial Protocol

Principal Investigator: Eric Weiss

Submission ID: BIO20240073

Applicable NIH Guidelines:

- Section III-F
- Section III-F-8-C-II
- Section III-F-1
- Section III-F-5
- Section III-F-8
- Section III-F-6

Containment Level: BSL-2

Approval Date: 5/21/2026

Continuing Review for BIO20240023

Continuing Review

Principal Investigator: Lisa Wilsbacher

Submission ID: BIO20240023-CR0002

Applicable NIH Guidelines:

- Section III-F
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2

Approval Date: 5/28/2026

Continuing Review for BIO20230109

Continuing Review

Principal Investigator: Steven Wolinsky

Submission ID: BIO20230109-CR0004

Applicable NIH Guidelines:

- Section III-F
- Section III-F-1
- Section III-D-2
- Section III-D
- Section III-D-3

Containment Level: BSL-2+

Approval Date: 6/8/2026

Continuing Review for BIO20220019

Continuing Review

Principal Investigator: Gayle Woloschak

Submission ID: BIO20220019-CR0001

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-C
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-D-3
- Section III-D-3-a
- Section III-F-8

Containment Level: BSL-2

Approval Date: 6/5/2026

Continuing Review for BIO20240103

Continuing Review

Principal Investigator: Yang Yi

Submission ID: BIO20240103-CR0002

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2+

Approval Date: 6/2/2026

Continuing Review for BIO20230044

Continuing Review

Principal Investigator: Feng Yue

Submission ID: BIO20230044-CR0003

Applicable NIH Guidelines:

- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 5/17/2026

Continuing Review for BIO20240030

Continuing Review

Principal Investigator: Christine Zhang

Submission ID: BIO20240030-CR0002

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-E-3
- Section III-E-3-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-D-2-a
- Section III-F-1
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2+

Approval Date: 6/8/2026

Other Agenda Items

Description:

Related Projects:

Notes: